| (Values in U.S. Thousands) | Apr, 2017 | Apr, 2016 | Apr, 2015 | Apr, 2014 | Apr, 2013 |
| Sales | 57,630 | 44,690 | 26,780 | 22,400 | 21,680 |
| Sales Growth | +28.96% | +66.88% | +19.55% | +3.32% | +42.35% |
| Net Income | -28,160 | -55,650 | -50,360 | -35,360 | -29,780 |
| Net Income Growth | +49.40% | -10.50% | -42.42% | -18.74% | +29.30% |
Peregrine Pharma New
(PPHM)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus infection. The company is pursuing three separate clinical trials in cancer and HCV infection with its lead product candidate bavituximab and Cotara. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and bio-manufacturing services for both Peregrine and outside customers.